Summitry LLC Sells 1,579 Shares of Cencora, Inc. $COR

Summitry LLC reduced its position in Cencora, Inc. (NYSE:COR) by 6.0% in the 2nd quarter, Holdings Channel reports. The firm owned 24,553 shares of the company’s stock after selling 1,579 shares during the quarter. Summitry LLC’s holdings in Cencora were worth $7,362,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of COR. Voleon Capital Management LP acquired a new stake in shares of Cencora in the first quarter valued at approximately $3,111,000. Focus Partners Wealth boosted its stake in Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after acquiring an additional 1,171 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the period. Martin Capital Partners LLC lifted its holdings in Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after acquiring an additional 2,544 shares in the last quarter. Finally, Fiduciary Alliance LLC acquired a new position in Cencora in the second quarter valued at about $262,000. 97.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on COR. Mizuho raised their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. TD Cowen raised their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by company insiders.

Cencora Price Performance

Shares of COR opened at $361.97 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $369.00. The stock has a market capitalization of $70.18 billion, a P/E ratio of 37.24, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a 50 day moving average of $321.35 and a 200-day moving average of $302.16.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.